Similarity between Flavonoid Biosynthetic Enzymes and Flavonoid Protein Targets Captured by Three-Dimensional Computing Approach

Abstract

Natural products are made by nature through interaction with biosynthetic enzymes. They also exert their effect as drugs by interaction with proteins. To address the question “Do biosynthetic enzymes and therapeutic targets share common mechanisms for the molecular recognition of natural products?”, we compared the active site of five flavonoid biosynthetic enzymes to 8077 ligandable binding sites in the Protein Data Bank using two three-dimensional-based methods (SiteAlign and Shaper). Virtual screenings efficiently retrieved known flavonoid targets, in particular protein kinases. A consistent performance obtained for variable site descriptions (presence/absence of water, variable boundaries, or small structural changes) indicated that the methods are robust and thus well suited for the identification of potential target proteins of natural products. Finally, our results suggested that flavonoid binding is not primarily driven by shape, but rather by the recognition of common anchoring points.

Key words

flavonoid - biosynthetic enzyme - natural product - binding site similarity

• References

• 1 Demain AL, Fang A. The natural functions of secondary metabolites. Adv Biochem Eng Biotechnol 2000; 69: 1-39
• 2 Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-335
• 3 Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Cote S, Shoichet BK, Urban L. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012; 486: 361-367
• 4 Kellenberger E, Schalon C, Rognan D. How to measure the similiarty between protein ligand-binding sites. Curr Comput Aided Drug Des 2008; 4: 209-220
• 5 McArdle BM, Campitelli MR, Quinn RJ. A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. J Nat Prod 2006; 69: 14-17
• 6 Kellenberger E, Hofmann A, Quinn RJ. Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs. Nat Prod Rep 2011; 28: 1483-1492
• 7 Gutmanas A, Alhroub Y, Battle GM, Berrisford JM, Bochet E, Conroy MJ, Dana JM, Fernandez Montecelo MA, van Ginkel G, Gore SP, Haslam P, Hatherley R, Hendrickx PM, Hirshberg M, Lagerstedt I, Mir S, Mukhopadhyay A, Oldfield TJ, Patwardhan A, Rinaldi L, Sahni G, Sanz-Garcia E, Sen S, Slowley RA, Velankar S, Wainwright ME, Kleywegt GJ. PDBe: Protein Data Bank in Europe. Nucleic Acids Res 2014; 42: D285-D291
• 8 Caspi R, Altman T, Dreher K, Fulcher CA, Subhraveti P, Keseler IM, Kothari A, Krummenacker M, Latendresse M, Mueller LA, Ong Q, Paley S, Pujar A, Shearer AG, Travers M, Weerasinghe D, Zhang P, Karp PD. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res 2012; 40: D742-D753
• 9 Desaphy J, Azdimousa K, Kellenberger E, Rognan D. Comparison and druggability prediction of protein-ligand binding sites from pharmacophore-annotated cavity shapes. J Chem Inf Model 2012; 52: 2287-2299
• 10 Consortium TU. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res 2014; 42: D191-D198
• 11 Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res 2000; 28: 45-48
• 12 Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, Kruger FA, Light Y, Mak L, McGlinchey S, Nowotka M, Papadatos G, Santos R, Overington JP. The ChEMBL bioactivity database: an update. Nucleic Acids Res 2014; 42: D1083-D1090
• 13 Sak K. Site-specific anticancer effects of dietary flavonoid quercetin. Nutr Cancer 2014; 66: 177-193
• 14 Peer WA, Murphy AS. The science of flavonoids. In: Grotewold E, editor Flavonoids as signal molecules: targets of flavonoid action. New York: Springer; 2006: 239-268
• 15 Lu X, Jung J, Cho HJ, Lim DY, Lee HS, Chun HS, Kwon DY, Park JH. Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 2005; 135: 2884-2890
• 16 Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002; 96: 67-202
• 17 Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000; 6: 909-919
• 18 Schalon C, Surgand JS, Kellenberger E, Rognan D. A simple and fuzzy method to align and compare druggable ligand-binding sites. Proteins 2008; 71: 1755-1778
• 19 Swets JA, Dawes RM, Monahan J. Better decisions through science. Sci Am 2000; 283: 82-87
• 20 Hawkins PC, Warren GL, Skillman AG, Nicholls A. How to do an evaluation: pitfalls and traps. J Comput Aided Mol Des 2008; 22: 179-190
• 21 Sturm N, Desaphy J, Quinn RJ, Rognan D, Kellenberger E. Structural insights into the molecular basis of the ligand promiscuity. J Chem Inf Model 2012; 52: 2410-2421
• 22 Puhl AC, Bernardes A, Silveira RL, Yuan J, Campos JL, Saidemberg DM, Palma MS, Cvoro A, Ayers SD, Webb P, Reinach PS, Skaf MS, Polikarpov I. Mode of peroxisome proliferator-activated receptor gamma activation by luteolin. Mol Pharmacol 2012; 81: 788-799
• 23 Ekinci D, Karagoz L, Ekinci D, Senturk M, Supuran CT. Carbonic anhydrase inhibitors: in vitro inhibition of alpha isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2013; 28: 283-288
• 24 El Amrani M, Lai D, Debbab A, Aly AH, Siems K, Seidel C, Schnekenburger M, Gaigneaux A, Diederich M, Feger D, Lin W, Proksch P. Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum . J Nat Prod 2014; 77: 49-56
• 25 Tasdemir D, Mallon R, Greenstein M, Feldberg LR, Kim SC, Collins K, Wojciechowicz D, Mangalindan GC, Concepcion GP, Harper MK, Ireland CM. Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem 2002; 45: 529-532
• 26 Desaphy J, Bret G, Rognan D, Kellenberger E. sc-PDB: a 3D-database of ligandable binding sites – 10 years on. Nucleic Acids Res 2015; 43: D399-D404
• 27 Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77-84